ISIssiaka Sombié

Issiaka Sombié

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Issiaka Sombié has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Science–policy translation for Lassa fever control in West Africa: a qualitative synthesis of regional evidence

    by Virgil Kuassi Lokossou, Aishat Bukola Usman, Issiaka Sombie, Oluomachukwu Omeje, Chukwuma David Umeokonkwo, Lionel Sogbossi, Ermel Johson, Bayode Romeo Adegbite, Kpatcha Tchamdja, Yves Mongbo, et al.

    Background: Lassa fever remains a major public health threat in West Africa, requiring coordinated scientific, policy, and financing responses. Regional scientific convenings are increasingly used to connect research evidence with policy action, yet their contribution to epidemic preparedness is not well documented. Methods: We conducted a qualitative health systems and policy analysis of the 2nd ECOWAS Lassa Fever International Conference (ELFIC 2025) in Abidjan, Côte d’Ivoire. Data sources comprised 302 scientific abstracts, plenary and ministerial session records, and the official Ministerial Joint Communiqué. Using the conference’s six thematic pillars as a deductive framework, we conducted a thematic content analysis and synthesized findings into four domains: scientific advances; surveillance and laboratory systems; policy and financing insights; and cross-cutting lessons for regional preparedness. Results: Progress was noted in diagnostics, therapeutics, vaccine development, decentralized laboratory capacity, genomic surveillance, and digital reporting. Persistent gaps remain at sub-national and community levels, in surveillance coverage, workforce capacity, and operational readiness. A major outcome was the Ministerial Joint Communiqué endorsing regional co-financing for Lassa fever vaccine development. Conclusion: ELFIC 2025 demonstrates the role of regional scientific platforms in aligning evidence with policy commitments. Sustained impact will require institutionalized coordination, strengthened accountability, and targeted investments in frontline capacity.

  • Open Access

    Situational Analysis of Community Health Systems in West Africa: Imperative to integrate social determinants of health

    by Emmanuel Ankrah Odame, David Houeto, Okpe Balle, Christian Osei, Ali Sani, Virgil Kuassi Lokossou, Keita Kissi, Namam Pansau, Placido Cardoso, Issiaka Sombié, et al.

    Introduction: The recent global pandemics and climate change, have exposed vulnerabilities in health systems; particularly in addressing community needs. In response, the West African Health Organization (WAHO) initiated a regional situational analysis to guide the update of the regional community health strategy, emphasizing the integration of social determinants of health (SDH). The objective of this situational assessment is to identify gaps in community health policies. Methods: A cross-sectional study was conducted through self-administered questionnaires, document reviews, and interviews with national community health stakeholders. Results: Thirteen countries participated. While all reported prioritizing data-driven interventions, only a few had community-specific HRH information systems. None had fully adopted a MEAL framework. Most countries employed two CHW categories—qualified professionals and volunteer workers—with core competencies often misaligned with SDH. Although supervision mechanisms existed in most cases, financing for community health remained inconsistent. The HiAP strategy was present in several countries but lacked full implementation or alignment with community needs. Conclusion: The analysis reveals critical gaps in institutional frameworks, financing, and workforce competencies in community health systems across West Africa. To achieve meaningful health outcomes, countries must shift from a fragmented approach to an integrated model that prioritizes social determinants of health.

  • Open Access

    A Prioritised Research Agenda to Inform the Introduction and Use of Lassa Fever Vaccines in West Africa

    by Melissa Ko, Virgil Kuassi Lokossou, Shamim Qazi, Thomas Cherian, Manuela Runge, Aishat Bukola Usman, Oyeronke Oyebanji, Chimezie Anueyiagu, Sharvani Saraf, Yetunde Abioye, et al.

    Background:Lassa fever is a viral haemorrhagic disease endemic in West Africa. While several vaccine candidates are in development, evidence to guide policy- and decision-making on vaccines remains limited. We convened a Policy Research Working Group (PRWG) to develop a prioritised research agenda to reduce delays related to policy- and decision-making on future Lassa fever vaccines.Methods:Using the Child Health and Nutrition Research Initiative (CHNRI) methodology, we conducted a two-phase prioritisation exercise. First, a rapid assessment of literature and expert interviews was conducted to identify evidence gaps, which were refined into 29 research questions across four thematic categories: epidemiology, vaccine trials, economic impact, and vaccine uptake. In phase two, 235 experts scored these questions using five criteria: answerability, effect on equity, potential for translation, relevance to context, and feasibility.Findings:Research Priority Scores (RPS) ranged narrowly from 80-92%, indicating the importance of the identified research questions. Thirteen research questions were prioritised, focusing on defining vaccination target groups, assessing vaccine efficacy in special populations, evaluating economic impact, and understanding vaccine acceptance. High expert agreement (67-85%) reinforced the robustness of the prioritisation outcomes.Interpretation:This stakeholder-driven agenda highlights the most critical evidence needs to guide vaccination policies, national decision-making, and implementation planning for future Lassa fever vaccines. Early alignment between research and policy can accelerate vaccine introduction and ensure equitable access in endemic regions.

  • Open Access

    An automated machine learning approach to predict glycaemic control in patients with type 2 diabetes in Burkina Faso

    by Cheick A. Ouattara, Bazoumana Coulibaly, Tiandiogo I. Traoré, Bakary Cissé, Carole G. Kyelem, Macaire S. Ouedraogo, Téné M. Yaméogo, Issiaka Sombié

    Background: Machine learning offers opportunities to improve risk stratification in type 2 diabetes by capturing complex clinical and sociodemographic interactions. Aim: To develop and evaluate machine learning models for predicting 1-year glycaemic control in patients with type 2 diabetes in Burkina Faso. Setting: A tertiary hospital in Burkina Faso, including patients followed up between 2020 and 2025. Methods: A retrospective cohort study included 424 patients. Glycaemic control was defined as glycated haemoglobin (HbA1c) < 7% at 1 year. Nine classifiers were trained using nested cross-validation. Performance was assessed using AUC-ROC, F1-score, recall, accuracy, precision and AUC-PR. Interpretability was assessed using SHAP (SHapley Additive exPlanations) with consensus feature importance ranking. Results: Overall, 42.9% of patients achieved glycaemic control at 1 year. Performance was moderate, with AUC-ROC ranging from 0.633 to 0.676 and no significant pairwise differences. AdaBoost performed best (AUC-ROC: 0.676). SHAP consistently identified baseline HbA1c, diabetes duration, total cholesterol, hypertension history and oral antidiabetic therapy as the most influential predictors. Conclusion: Machine learning models showed moderate, comparable performance, suggesting a ceiling imposed by routinely available data. Baseline HbA1c and diabetes duration were dominant predictors. Future research should prioritise external validation and longitudinal data integration. Contribution: This study provides evidence supporting machine learning for identifying key predictors of glycaemic control in West Africa, offering clinically actionable insights and highlighting the need for context-adapted decision-support tools in resource-limited settings.

  • Open Access

    Strengthening the mpox response: how do we balance pragmatism and equity in resource-constrained settings?

    by Virgil K Lokossou, Kehinde O Ogunyemi, Aishat B Usman, Simplice Kamdem, Césaire D Ahanhanzo, Felix Agbla, Melchior A Aïssi, Issiaka Sombié

    Mpox, formerly monkeypox, is an infectious zoonotic disease caused by the monkeypox virus (MPXV) characterised by skin rash, often accompanied by fever, muscle aches, headache, and other symptoms lasting 2–4 weeks [1]. It was responsible for a large mpox outbreak between July 2022 and July 2023 that affected more than 110 countries. This resulted in […]


  • Open Access

    Assessing mpox epidemic readiness status in ECOWAS region: strengths, gaps, and recommendations for an improved response

    by Virgil Kuassi Lokossou, Andrew Sime Awori, Victor Fatimehin, Aishat Bukola Usman, Lionel Sogbossi, Felix Agbla, Melchior Athanase Aïssi, Issiaka Sombie

    Mpox (formerly known as monkeypox) has re-emerged as a significant public health threat in West Africa, creating new challenges for regional and national health systems. Drawing from past outbreaks, the West African Health Organization (WAHO) has been proactive in enhancing public health preparedness, aligned with WHO recommendations. This study aims to assess the readiness of the ECOWAS region to manage the ongoing mpox outbreak, focusing on critical areas of national epidemic preparedness and response. A survey using the WHO mpox-epidemic readiness checklist tool was conducted in 14 ECOWAS Member States from August 25 to September 15, 2024. Key stakeholders, including Directors of Public Health and Heads of National Public Health Institutes, participated in the assessment. Mpox preparedness meetings and training reports from WAHO were also reviewed to evaluate the region’s efforts. A thematic analysis identified key themes, strengths, challenges, and gaps in mpox readiness. The findings revealed considerable variations in readiness across ECOWAS countries. Strengths include established coordination structures, operational surveillance systems, and developed risk communication plans. However, there are major gaps in laboratory capacity, case management, and logistics. Countries such as Liberia and Guinea-Bissau lack sufficient healthcare workers and ICU facilities for managing severe mpox cases. In Senegal and The Gambia, inadequate adaptation and translation of Information, Education, and Communication (IEC) materials hamper public awareness. Logistic challenges, particularly the absence of emergency supply mechanisms and cold chain capacity, also hinder effective responses. Despite progress in mpox preparedness, ECOWAS countries must address significant gaps in laboratory capacity, healthcare infrastructure, and logistics through enhanced coordination and investments.


  • Open Access

    Promoting Institutionalization of Research-Evidence Use in Maternal, Newborn and Child-Health Policymaking in Nigeria

    by Chigozie Jesse Uneke, Issiaka Sombie, Ermel Johnson, Onyedikachi Echefu Chukwu, Bilikis Iyabo Uneke, Kingsley Otubo Igboji

    The implementation of policies informed by research evidence in maternal newborn and child health (MNCH) is known to improve health outcomes. In this study we describe the process of the establishment of MNCH Research Days Event as a mechanism for the promotion of institutionalization of evidence-to-policy-to practice in MNCH in Nigeria. We also describe the current status of research evidence use in policymaking, level of policymakers-researchers interaction as well as identify the individual and organizational roles to promote evidence-informed policymaking in MNCH in Nigeria. The study was a cross-sectional survey carried out during a 3-day National MNCH stakeholders’ engagement meeting on Nigeria Research Days for MNCH, as part of the Implementation of Moving MNCH Evidence into Policy (MEP) Project. Data on the stakeholders’ perception regarding the study objective was collected using a semi-structured questionnaire administered in person. A total of 51 participants completed the questionnaire. Result showed low mean ratings (MNRs) for both research evidence use in MNCH policymaking (ranging from 2.23-3.14 in a 5-point scale) and policymakers-researchers interaction (2.98-3.43). Creating research capacity development platforms for individuals and institutions involved in policymaking (MNR 4.69) were among strategies that can enhance the evidence-to-policy process in MNCH. Sustainable interaction between policymakers and researchers can be achieved through the institutionalization of mechanisms such as ‘Research Day Event’ that will provide platform to consider issues around evidence-to-policy-to-practice. Urgent sustainable capacity development among stakeholders in the MNCH sector is highly recommended.

  • Open Access

    Surveillance of Antimicrobial Resistance in the ECOWAS Region: Setting the Scene for Critical Interventions Needed

    by Ahmed Taha Aboushady, Olivier Manigart, Abdourahmane Sow, Walter Fuller, Abdoul-Salam Ouedraogo, Chinelo Ebruke, François-Xavier Babin, Laetitia Gahimbare, Issiaka Sombié, John Stelling

    Antimicrobial resistance poses a significant challenge to public health globally, leading to increased morbidity and mortality. AMR surveillance involves the systematic collection, analysis, and interpretation of data on the occurrence and distribution of AMR in humans, animals, and the environment for action. The West African Health Organization, part of the Economic Community of West African States (ECOWAS), is committed to addressing AMR in the region. This paper examines the status of AMR surveillance in ECOWAS countries using available WHO data from the TrACSS survey and GLASS enrollments. The analysis reveals that while progress has been made, significant challenges remain. Twelve of the fifteen ECOWAS countries are enrolled in GLASS, and ten have developed national action plans (NAPs) for AMR. However, there is a need to ensure all countries fully implement their NAPs, continue reporting to GLASS, and use the data for evidence-based actions and decision making. Surveillance systems for AMR and antimicrobial consumption/use vary across countries with some demonstrating limited capacity. All countries, except Cabo Verde, reported having a reference laboratory for AMR testing. Strengthening laboratory capabilities, data management and use, and multisectoral coordination are crucial for effective AMR surveillance and response. Based on the findings and the regional context, it is essential to prioritize capacity building, data utilization, and the adoption of standardized guidelines for AMR surveillance. Collaboration among ECOWAS countries, the WAHO, and international partners is essential to address AMR comprehensively. Ensuring a consistent supply of essential antimicrobial medications and reagents is vital.


  • Open Access

    Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger

    by Anyirékun Fabrice Somé, Issaka Zongo, Issaka Sagara, Alkassoum Ibrahim, Césaire Damien Ahanhanzo, Edoh Eddie Agbanouvi-Agassi, Dona Alain Sayi, Lea Pare Toe, Zachari Kabré, Frédéric Nikiéma, et al.

    This study aims to evaluate the factors influencing the adherence to the 2nd and 3rd doses of Amodiaquine (AQ) during seasonal malaria chemoprevention (SMC) in Burkina Faso, Mali, and Niger. Overall, 3132 people were interviewed during surveys between 2019 and 2020 in 15 health districts. In Burkina Faso, Mali, and Niger, the proportions of non-adherence were 4.15%, 5.60%, and 13.30%, respectively, for the 2nd dose and 3.98%, 5.60% and 14.39% for the 3rd dose. The main cause of non-adherence to the 2nd and 3rd doses was other illnesses in 28.5% and 29.78%, respectively, in Burkina Faso, 5.35% and 5.35% in Mali and 1.6% and 0.75% in Niger. It was followed by vomiting in 12.24% and 10.63% for Burkina and 2.45% and 3.78% in Niger. The last cause was refusal in 6.12% and 4.25% in Burkina, 33.9% and 15.25% in Mali and 0.8% and 1.51% in Niger. Non-adherence of doses related to parents was primarily due to their absence in 28.5% and 27.65% in Burkina, 16.07% and 16.07% in Mali and 7.37% and 6.06% in Niger. Traveling was the second cause related to parents in 12.24% and 12.76% in Burkina, 19.64% and 19.64% in Mali and 0.81% and 0.75% in Niger. Non-adherence related to community distributors was mainly due to missing the doses in 4.08% and 4.25% in Burkina, 23.21% and 23.21% in Mali, 77.04% and 76.51% in Niger. Our study reported very small proportions of non-adherence to 2nd and 3rd doses of SMC and identified the main causes of non-adherence. These findings will provide helpful information for policymakers and public health authorities to improve adherence to SMC


  • Open Access

    Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali, and Niger

    by Anyirékun Fabrice Somé, Issaka Zongo, Issaka Sagara, Alkassoum Ibrahim, Césaire Damien Ahanhanzo, Edoh Eddie Agbanouvi-Agassi, Dona Alain Sayi, Lea Paré, Zachari Kabré, Frédéric Nikiéma, et al.

    This study aims to evaluate the factors influencing the adherence to the 2nd and 3rd doses during each cycle of seasonal malaria chemoprevention (SMC) in Burkina Faso, Mali, and Niger. Overall, 3,132 people were interviewed during surveys between 2019 and 2020 in 15 health districts. The median age was 30 years. In Burkina , Mali, and Niger, the proportions of non-adherence were 4.15% , 5.60%, and 13.30%, respectively (95% CI (-3.27% -0.37 %, p = 0.114 ) for the 2nd dose and 3.98%, 5.60% and 14.39% for the 3rd dose. The main cause of non-adherence to the 2nd and 3rd doses was other illnesses in 28.5% and 29.78% respectively in Burkina, 5.35% and 5.35% in Mali and 1.6% and 0.75% in Niger. It was followed by vomiting in 12.24% and 10.63% for Burkina and 2.45% and 3.78% in Niger. The last causes were refusal in 6.12% and 4.25% in Burkina , 33.9% and 15.25% in Mali and 0.8% and 1.51% in Niger. Non-adherence of doses related to parents was primary due to their absence in 28.5% and 27.65% in Burkina , 16.07% and 16.07% in Mali and 7.37 % and 6.06% in Niger. Travelling was the second cause in 12.24 % and 12.76% in Burkina , 19.64% and 19.64% in Mali and 0.81% and 0.75% in Niger. Non-adherence related to community distributors was mainly due to missing of the doses in 4.08% and 4.25% in Burkina , 23.21% and 23.21% in Mali, 77.04% and 76.51% in Niger. Our study reported very small proportions of non-adherence to 2nd and 3rd doses of SMC and identified the main causes of non-adherence.